ATE468859T1 - Immunogene zusammensetzung und verfahren - Google Patents

Immunogene zusammensetzung und verfahren

Info

Publication number: ATE468859T1
Authority: AT; Austria
Prior art keywords: mammalian; subject; rvsv; composition; effective amount
Prior art date: 2003-03-26

Application number

AT04722764T

Other languages

English (en)

Inventor

John Eldridge

Zimra Israel

Michael Egan

Stephen A Udem

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-26

Filing date

2004-03-23

Publication date

2010-06-15

2004-03-23 Application filed by Wyeth Llc filed Critical Wyeth Llc

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE468859T1 publication Critical patent/ATE468859T1/de

Links

238000000034 method Methods 0.000 title abstract 4
230000002163 immunogen Effects 0.000 title 1
239000000427 antigen Substances 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 3
108091007433 antigens Proteins 0.000 abstract 3
108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
230000001105 regulatory effect Effects 0.000 abstract 2
108020004414 DNA Proteins 0.000 abstract 1
241000711975 Vesicular stomatitis virus Species 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
239000013612 plasmid Substances 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Mycology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Biophysics (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04722764T 2003-03-26 2004-03-23 Immunogene zusammensetzung und verfahren ATE468859T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US45787603P	2003-03-26	2003-03-26
US54673304P	2004-02-23	2004-02-23
PCT/US2004/006089 WO2004093906A1 (en)	2003-03-26	2004-03-23	Immunogenic composition and methods

Publications (1)

Publication Number	Publication Date
ATE468859T1 true ATE468859T1 (de)	2010-06-15

Family

ID=42828775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04722764T ATE468859T1 (de)	2003-03-26	2004-03-23	Immunogene zusammensetzung und verfahren

Country Status (13)

Country	Link
US (2)	US20070134200A1 (de)
EP (1)	EP1605971B1 (de)
JP (1)	JP2006523224A (de)
CN (1)	CN1764474B (de)
AT (1)	ATE468859T1 (de)
AU (1)	AU2004231464B2 (de)
BR (1)	BRPI0408779A (de)
CA (1)	CA2517010C (de)
DK (1)	DK1605971T3 (de)
MX (1)	MXPA05008526A (de)
NZ (1)	NZ542652A (de)
PL (1)	PL1605971T3 (de)
WO (1)	WO2004093906A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6861422B2 (en)	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
PT1605971E (pt) *	2003-03-26	2010-07-29	Wyeth Llc	COMPOSIÃ†O IMUNOGéNICA E MéTODOS
TW200613554A (en)	2004-06-17	2006-05-01	Wyeth Corp	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
DE102004029784A1 (de)	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de)	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en)	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en)	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en)	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060074088A1 (en)	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de)	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de)	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2006110344A1 (en) *	2005-04-07	2006-10-19	Wyeth	Novel methods for inducing an immune response against human immunodefiency virus
US7439358B2 (en)	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2185559A1 (de)	2007-08-03	2010-05-19	Boehringer Ingelheim International GmbH	Kristalline form eines dihydropteridionderivats
BRPI1009616B8 (pt) *	2009-06-08	2021-05-25	Univ Western Ontario	plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit
WO2011041433A1 (en) *	2009-09-29	2011-04-07	The Trustees Of The University Of Pennsylvania	Methods for diagnosing and treating encephalitis or epilepsy
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
UY33821A (es) *	2010-12-22	2012-07-31	Bayer Animal Health Gmbh	Respuesta inmune potenciada en la especie bovina
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors
US20150031699A1 (en)	2013-07-26	2015-01-29	Boehringer Ingelheim International Gmbh	Treatment of myelodysplastic syndrome
EP3110940A1 (de)	2014-02-28	2017-01-04	Bayer Animal Health GmbH	Immunstimulierende plasmide
ES2749381T3 (es) *	2014-03-01	2020-03-20	Univ Texas	Vectores víricos Isfahan recombinantes
US9867831B2 (en)	2014-10-01	2018-01-16	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
AU2016302436B2 (en)	2015-07-31	2022-03-03	Elanco Animal Health Gmbh	Enhanced immune response in porcine species
CN105567646B (zh) *	2016-02-22	2019-01-01	浙江大学	分泌抗甘蔗花叶病毒单抗杂交瘤细胞株及其单抗应用
CN113968907B (zh) *	2020-07-22	2023-05-26	中国人民解放军军事科学院军事医学研究院	具有中和活性的抗尼帕病毒单克隆抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL59007A (en) *	1978-12-22	1983-11-30	Biogen Nv	Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5593972A (en) *	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
US7153510B1 (en) *	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
EP1280551B1 (de) *	2000-04-27	2007-01-10	Sanofi Pasteur Limited	Impfstoffe gegen hiv
US20030021805A1 (en) *	2001-05-29	2003-01-30	Barber Glen N.	Generation of HCV-like particles and chimeric HCV virus
US20030044386A1 (en) *	2001-07-11	2003-03-06	Barber Glen N.	Recombinant VSV for the treatment of tumor cells

2004
- 2004-03-23 US US10/550,313 patent/US20070134200A1/en not_active Abandoned
- 2004-03-23 BR BRPI0408779-8A patent/BRPI0408779A/pt not_active Application Discontinuation
- 2004-03-23 NZ NZ542652A patent/NZ542652A/en unknown
- 2004-03-23 AU AU2004231464A patent/AU2004231464B2/en not_active Expired
- 2004-03-23 PL PL04722764T patent/PL1605971T3/pl unknown
- 2004-03-23 JP JP2006508920A patent/JP2006523224A/ja not_active Withdrawn
- 2004-03-23 WO PCT/US2004/006089 patent/WO2004093906A1/en not_active Ceased
- 2004-03-23 MX MXPA05008526A patent/MXPA05008526A/es active IP Right Grant
- 2004-03-23 EP EP04722764A patent/EP1605971B1/de not_active Expired - Lifetime
- 2004-03-23 DK DK04722764.0T patent/DK1605971T3/da active
- 2004-03-23 CN CN2004800078180A patent/CN1764474B/zh not_active Expired - Lifetime
- 2004-03-23 CA CA2517010A patent/CA2517010C/en not_active Expired - Lifetime
- 2004-03-23 AT AT04722764T patent/ATE468859T1/de active
2012
- 2012-04-24 US US13/454,884 patent/US20120244113A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1764474B (zh)	2011-02-02
CA2517010A1 (en)	2004-11-04
WO2004093906A1 (en)	2004-11-04
NZ542652A (en)	2008-04-30
DK1605971T3 (da)	2010-08-16
JP2006523224A (ja)	2006-10-12
MXPA05008526A (es)	2005-10-20
PL1605971T3 (pl)	2010-10-29
CN1764474A (zh)	2006-04-26
CA2517010C (en)	2013-09-24
AU2004231464A1 (en)	2004-11-04
AU2004231464B2 (en)	2010-08-05
BRPI0408779A (pt)	2006-04-04
US20120244113A1 (en)	2012-09-27
US20070134200A1 (en)	2007-06-14
EP1605971A1 (de)	2005-12-21
EP1605971B1 (de)	2010-05-26

Legal Events

Date

Code

Title

Description

2010-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1605971

Country of ref document: EP

Publication	Publication Date	Title
ATE468859T1 (de)	2010-06-15	Immunogene zusammensetzung und verfahren
Chang et al.	2015	Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model
US11478544B2 (en)	2022-10-25	Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes
DE69835085D1 (de)	2006-08-10	Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
Konishi et al.	1994	A vipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens
BRPI0414381A (pt)	2006-11-21	composição de adjuvante, composição ou composições imunogênica(s), composição de vacina, processo para a fabricação de uma composição imunogênica, composição ou composições farmacêutica(s), kit, métodos para tratar um paciente que sofre de, ou que é suscetìvel a, um tumor, para incrementar uma resposta imune de um mamìfero a um antìgeno e para suscitar uma resposta imune em m mamìfero contra um estado de doença, usos de uma imidazoquinolina ou derivado da mesma e gm-csf e dos componentes
ATE127345T1 (de)	1995-09-15	Stressproteine und verwendungen dafür.
KR20200101416A (ko)	2020-08-27	B형 간염 바이러스(hbv) 백신 및 그 용도
Shi et al.	2006	Expressions of Bovine IFN-γ and Foot-and-Mouth Disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigens
Liu et al.	1998	DNA vaccines: mechanisms for generation of immune responses
Appelberg et al.	2022	A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells
Kawai et al.	2023	Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses
BR9812240A (pt)	2000-07-18	Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica
Lodmell et al.	2001	Post-exposure DNA vaccination protects mice against rabies virus
MXPA02005506A (es)	2004-09-10	Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
DE60026588D1 (de)	2006-05-04	Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
BR0206112A (pt)	2005-05-10	Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
CO2025015946A2 (es)	2025-11-28	Método para inducir una respuesta inmunitaria
RU2015121429A (ru)	2016-12-27	Химерные антигены для вакцины против вируса гепатита с
BRPI0209416A2 (pt)	2004-03-30	Novos vetores de expressão e uso dos mesmos
Attreed et al.	2024	Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle
CY1110205T1 (el)	2015-01-14	Ανοσογονος συνθεση και μεθοδοι
FR2724385B1 (fr)	1996-12-13	Vaccin de la peritonite infectieuse feline.
Paolucci et al.	2025	Intralymphatic Administration of Naked mRNA Induces Allergen‐Specific IgG, Promotes Th1 Responses and Reduces Anaphylactic Potential.
CN100594931C (zh)	2010-03-24	一种猪疫苗使用的pIFN-γ基因佐剂及制备方法